AbbVie is trading 3.1% up at $264.85 as investors position ahead of its July 31, 2026, Q2 earnings release.
- Recent analyst price-target increases and optimism around the immunology pipeline, including new regulatory filings for Rinvoq and Skyrizi, are driving renewed enthusiasm.
- The stock is further supported by a strong broader rally across the healthcare sector.